Teva’s $420M Samsung Bioepis Deal Includes Biosimilar Banned From US Until 2029 Patent Expires
Teva and Samsung Bioepis agreed to a $420M deal for two biosimilars. Teva gains US rights to RENFLEXIS (infliximab-abda), which can be sold immediately, and ETICOVO (etanercept-ykro), blocked from US sales until 2029 due to patent disputes. The deal includes upfront, launch, and sales milestones. Teva aims to leverage its distribution network to boost RENFLEXIS's market share, while ETICOVO's launch is delayed by legal restrictions.
How this was made
The 30-second read
Why it matters
Traders should separate the deal into an immediately monetizable infliximab biosimilar (RENFLEXIS) and a legally delayed etanercept biosimilar (ETICOVO), with the latter constrained by Roche-owned patents and court-ordered destruction of imported product.
Market read
A large biosimilar licensing deal is announced, but enforceable US patent litigation keeps one product off US shelves until 2029, shaping near-term vs long-term value expectations.
What to watch
Market access depends on payer formulary negotiations and prescriber adoption since neither biosimilar is designated interchangeable, which could cap realized share even for RENFLEXIS.
Background
Samsung Bioepis and Teva agreed to license two FDA-approved biosimilars in the US, but a 2021 permanent injunction blocks one product (ETICOVO) until patent expiry in 2028/2029.
Ticker impact
Teva announced a licensing and commercialization deal worth up to $420M, but only RENFLEXIS is sellable now while ETICOVO remains blocked until 2029.
Likely modest positive bias for Teva from the immediately commercializable RENFLEXIS rights, partially offset by the long delay and legal overhang on ETICOVO.
The article specifies the deal structure and explicitly states RENFLEXIS is immediately commercializable while ETICOVO cannot be sold in the US until at least April 24, 2029 due to a permanent injunction.
Market effects
Reinforces that biosimilar market access can be constrained by layered biologic patent estates, even after FDA approval.
US biosimilar competitive landscape for infliximab and etanercept is split, with infliximab competition advancing while etanercept remains blocked.
Highlights cross-border licensing dynamics between US generic players and global biologics specialists, with US patent enforcement driving commercialization timing.
Counterpoint
The headline $420M may understate risk because most value is milestone-based and ETICOVO’s launch is legally deferred, limiting near-term earnings sensitivity.
Key entities
- companyTeva Pharmaceuticals
US rights holder under a licensing and commercialization agreement for RENFLEXIS and ETICOVO, with RENFLEXIS immediately commercializable and ETICOVO blocked until 2029.
- companySamsung Bioepis
Licensor of the two biosimilars; subject of the US court injunction preventing ETICOVO sales until at least April 24, 2029.
- companyRoche
Patent owner whose Enbrel-related patents underpinned the injunction blocking ETICOVO in the US.
- companyAmgen
Holds the Enbrel monopoly described as running until April 2029, benefiting from the blocked etanercept biosimilar competition.
